Syndax制药 SNDX 深 沪
等待开盘 06-30 09:30:00 美东时间
21.78
+0.470
+2.21%
华盛通- 最 高22.05
- 今 开21.20
- 成交量 421.14万股
- 最 低 20.86
- 昨 收 21.31
- 总市值 19.30亿
- 52周最高 25.59
- 市盈率 静 --
- 换手率 4.75%
- 52周最低 8.585
- 委 比 -37.12%
- 总股本 8861.00万
- 历史最高 29.86
- 量 比 1.89
- 振 幅 5.58%
- 历史最低 3.39
- 每 手 1
- 风险率 4.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed pati...
06-11 19:09
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals announced positive results from the Phase 1/2 SAVE trial of Revuforj® (revumenib) in relapsed or refractory acute myeloid leukemia (AML). The all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax achieved an 88% overall response rate (ORR) and 71% composite complete remission (CRc) rate in heavily pretreated patients. Notably, 45% of patients proceeded to stem cell transplant, and the combination was ge...
06-11 11:00
Syndax Pharmaceuticals Reports New Significant Financial Obligation Agreement
Syndax Pharmaceuticals ( ($SNDX) ) has shared an update. Syndax Pharmaceuticals...
06-11 06:36
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted stock options to four new employees on June 1, 2026, under the 2023 Inducement Plan. The options, totaling 66,700 shares, vest over four years, with 25% after the first year and monthly thereafter. The company, focused on innovative cancer therapies, has FDA-approved products Revuforj and Niktimvo and is conducting clinical trials to expand its pipeline potential.
06-04 20:01
Syndax Pharmaceuticals prices $250M senior convertible notes
Commercial-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) entered into privately negotiated agreements for the issuance of $250M 2.25% convertible senior notes due 2031. The sale of th...
06-04 19:35
Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute Leukemia
Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New
06-01 19:11
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Pharmaceuticals will host an R&D Day on July 14, 2026, in New York City, featuring presentations by its management team and key opinion leaders. The event will highlight its late-stage revumenib and axatilimab programs, including ongoing trials in idiopathic pulmonary fibrosis, chronic graft-versus-host disease, and acute leukemia. The Company will also detail its early-stage assets and plans to expand treatment options for patients. A liv...
06-01 11:00
Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –– Data underscoring unique aspects of
05-22 05:05
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals announced the acceptance of four Revuforj (revumenib) abstracts for presentation at the 2026 ASCO Annual Meeting. Key highlights include an oral presentation on favorable outcomes in 21 adults and children with acute leukemia treated with revumenib post-transplant, as well as posters on its pharmacokinetics, including administration with gastric acid reducers and low-fat meals. Ongoing pivotal trials combining revumenib wit...
05-21 21:01
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals, a biopharmaceutical company focused on innovative cancer therapies, announced that CEO Michael A. Metzger and the management team will participate in three upcoming investor conferences: the TD Cowen Oncology Innovation Summit on May 27, 2026; the Jefferies Global Healthcare Conference on June 4, 2026; and the Goldman Sachs Global Healthcare Conference on June 8, 2026. Live webcasts of the fireside chats will be available ...
05-20 11:00
